boehringer ingelheim glp-1 New Endorsement of the GLP-1-FGF21 Dual Agonist Approach ADA: Tolerability questions linger for

Potential Risks While most reviews describe a smooth experience, some users report: Digestive discomfort in the early adjustment phase Mild stool changes as the gut adapts to new bacteria Delayed results , which may lead to frustration if expectations are unrealistic It's important to remember that probiotics affect everyone differently

Importantly, weight loss with GLP-1 therapy extends beyond aesthetics: participants showed meaningful reductions in blood pressure, triglycerides, and inflammation markers associated with cardiovascular disease

Minoxidil has FDA approval since 1988

Or your provider may require you to show evidence that other strategies have failed first (e.g

10.1038/nature26000 18